Russell Investments Group, Ltd. Xencor Inc Transaction History

Russell Investments Group, Ltd.

  • $70.2 Billion
  • Q1 2025

A detailed history of Russell Investments Group, Ltd. transactions in Xencor Inc stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 34,708 shares of XNCR stock, worth $323,825. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,708
Previous 216,291 83.95%
Holding current value
$323,825
Previous $4.97 Million 92.58%
% of portfolio
0.0%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 13, 2025
SELL
$10.64 - $24.13 $1.93 Million - $4.38 Million
-181,583 Reduced 83.95%
34,708 $369,000
Q4 2024

Feb 13, 2025
SELL
$19.43 - $26.84 $325,141 - $449,140
-16,734 Reduced 7.18%
216,291 $4.97 Million
Q3 2024

Nov 13, 2024
BUY
$15.7 - $21.65 $321,316 - $443,088
20,466 Added 9.63%
233,025 $4.69 Million
Q2 2024

Aug 08, 2024
SELL
$18.21 - $24.5 $210,890 - $283,734
-11,581 Reduced 5.17%
212,559 $4.02 Million
Q1 2024

May 08, 2024
BUY
$18.65 - $26.52 $1.26 Million - $1.79 Million
67,522 Added 43.11%
224,140 $4.96 Million
Q4 2023

Feb 05, 2024
BUY
$16.53 - $21.42 $394,934 - $511,766
23,892 Added 18.0%
156,618 $3.33 Million
Q3 2023

Nov 13, 2023
BUY
$20.08 - $25.39 $71,143 - $89,956
3,543 Added 2.74%
132,726 $2.67 Million
Q2 2023

Aug 10, 2023
BUY
$24.77 - $29.9 $360,031 - $434,596
14,535 Added 12.68%
129,183 $3.23 Million
Q1 2023

May 09, 2023
SELL
$25.95 - $36.95 $137,924 - $196,389
-5,315 Reduced 4.43%
114,648 $3.2 Million
Q4 2022

Feb 08, 2023
SELL
$24.79 - $30.86 $473,067 - $588,901
-19,083 Reduced 13.72%
119,963 $3.12 Million
Q3 2022

Nov 04, 2022
SELL
$24.62 - $32.44 $598,635 - $788,778
-24,315 Reduced 14.88%
139,046 $3.61 Million
Q2 2022

Jul 29, 2022
BUY
$19.74 - $29.01 $642,714 - $944,536
32,559 Added 24.89%
163,361 $4.47 Million
Q1 2022

May 05, 2022
BUY
$26.68 - $41.63 $772,119 - $1.2 Million
28,940 Added 28.41%
130,802 $3.49 Million
Q4 2021

Jan 21, 2022
BUY
$33.67 - $43.44 $65,589 - $84,621
1,948 Added 1.95%
101,862 $4.09 Million
Q3 2021

Nov 08, 2021
BUY
$30.65 - $35.68 $479,243 - $557,892
15,636 Added 18.55%
99,914 $3.26 Million
Q2 2021

Aug 04, 2021
BUY
$34.33 - $44.68 $1.61 Million - $2.09 Million
46,870 Added 125.29%
84,278 $2.91 Million
Q1 2021

May 10, 2021
SELL
$40.81 - $53.88 $353,169 - $466,277
-8,654 Reduced 18.79%
37,408 $1.61 Million
Q4 2020

Feb 08, 2021
SELL
$36.63 - $47.63 $286,226 - $372,180
-7,814 Reduced 14.5%
46,062 $2.01 Million
Q3 2020

Nov 09, 2020
SELL
$30.09 - $43.02 $260,308 - $372,166
-8,651 Reduced 13.84%
53,876 $2.09 Million
Q2 2020

Aug 05, 2020
BUY
$27.76 - $33.42 $547,593 - $659,242
19,726 Added 46.09%
62,527 $2.02 Million
Q1 2020

May 06, 2020
BUY
$20.69 - $37.79 $385,578 - $704,254
18,636 Added 77.12%
42,801 $1.28 Million
Q4 2019

Jan 29, 2020
BUY
$32.75 - $41.43 $789,176 - $998,338
24,097 Added 35436.76%
24,165 $830,000
Q3 2019

Nov 01, 2019
BUY
$33.73 - $46.27 $2,293 - $3,146
68 New
68 $2,000
Q2 2019

Aug 09, 2019
SELL
$29.6 - $40.93 $438,820 - $606,787
-14,825 Closed
0 $0
Q1 2019

May 13, 2019
SELL
$27.85 - $38.09 $187,040 - $255,812
-6,716 Reduced 31.18%
14,825 $460,000
Q4 2018

Feb 11, 2019
BUY
$32.39 - $42.05 $697,712 - $905,799
21,541 New
21,541 $779,000
Q2 2018

Aug 08, 2018
SELL
$28.41 - $42.41 $1.31 Million - $1.96 Million
-46,144 Closed
0 $0
Q1 2018

May 11, 2018
SELL
$21.18 - $33.78 $540,026 - $861,288
-25,497 Reduced 35.59%
46,144 $1.38 Million
Q4 2017

Feb 06, 2018
BUY
$19.29 - $24.83 $93,556 - $120,425
4,850 Added 7.26%
71,641 $1.62 Million
Q3 2017

Nov 07, 2017
BUY
$19.61 - $23.35 $1.31 Million - $1.56 Million
66,791
66,791 $1.53 Million

Others Institutions Holding XNCR

# of Institutions
207
Shares Held
78.4M
Call Options Held
3.4K
Put Options Held
1.9K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $557M
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email